Cubosomes: The Next Generation of Nanomedicine Delivery Systems in Cancer Treatment

Many conventional and adjuvant anticancer therapies can have serious adverse effects or yield subpar therapeutic results, and thus nanomedicine has begun to gain appeal for treating cancer. A family of nanocarriers called cubosomes exhibits promis-ing theragnostic efficacy. They are self-assembling, honeycomb-like, three-dimensional structures in the bicontinuous cubic liquid crystalline phase. They have a large interfacial area, straightforward preparation, capacity to encapsulate hydropho-bic, hydrophilic, and amphiphilic moieties, biodegradability, and targeted and controlled release of bioactive freight. Targeted drug delivery and a decrease in drug resistance have been accomplished by cubosomes. Cubosomes have also been employed in immunotherapy as a component of cancer medication therapy. Studies have revealed that the pharmacokinetics and safety characteristics of loaded medicines are enhanced by cubosomes. Cubosomes have been used in numerous preclinical trials to treat cancer and for theragnostic purposes. This review reports the most recent studies on the application of cubosomes in vitro and in vivo experimental models for the treatment of various neoplastic illnesses. The review highlights that cubosomes provide a flexible and promising platform for the administration of medicinal drugs.